Echo Therapeutics Performance
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Echo Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Echo Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Echo Therapeutics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Quick Ratio | 0.02 | |
| Fifty Two Week Low | 0.0001 | |
| Target High Price | 2.00 | |
| Fifty Two Week High | 0.2800 | |
| Target Low Price | 2.00 |
Echo |
Echo Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Echo Therapeutics on January 26, 2024 and sell it today you would earn a total of 100.00 from holding Echo Therapeutics or generate -100.0% return on investment over 90 days. Echo Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Echo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Echo Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Echo Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Echo Therapeutics, and traders can use it to determine the average amount a Echo Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ECTE |
Based on monthly moving average Echo Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Echo Therapeutics by adding Echo Therapeutics to a well-diversified portfolio.
Echo Therapeutics Fundamentals Growth
Echo Stock prices reflect investors' perceptions of the future prospects and financial health of Echo Therapeutics, and Echo Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Echo Stock performance.
| Return On Equity | -3.65 | |||
| Return On Asset | -359.77 | |||
| Current Valuation | 3.43 M | |||
| Shares Outstanding | 12 M | |||
| Price To Earning | (0.03) X | |||
| Price To Book | 3.11 X | |||
| Price To Sales | 990.09 X | |||
| Revenue | 5.12 K | |||
| EBITDA | (5.18 M) | |||
| Cash And Equivalents | 172.72 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 3.52 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | (0.55) X | |||
| Cash Flow From Operations | (4.82 M) | |||
| Earnings Per Share | (1.10) X | |||
| Total Asset | 805.09 K | |||
| Retained Earnings | (145.78 M) | |||
| Current Asset | 300.74 K | |||
| Current Liabilities | 3.24 M |
Things to note about Echo Therapeutics performance evaluation
Checking the ongoing alerts about Echo Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Echo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Echo Therapeutics is not yet fully synchronised with the market data | |
| Echo Therapeutics has some characteristics of a very speculative penny stock | |
| Echo Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company currently holds 3.52 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Echo Therapeutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Echo Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Echo Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Echo Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Echo to invest in growth at high rates of return. When we think about Echo Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 5.12 K. Net Loss for the year was (12.5 M) with profit before overhead, payroll, taxes, and interest of 5.12 K. | |
| Echo Therapeutics currently holds about 172.72 K in cash with (4.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
- Analyzing Echo Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Echo Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Echo Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Echo Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Echo Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Echo Therapeutics' stock. These opinions can provide insight into Echo Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Echo Stock
If you are still planning to invest in Echo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Echo Therapeutics' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |